Lipella Pharmaceuticals Inc. (LIPO) Earnings History
Net Loss6 years of earnings data (2019–2024) · Currently unprofitable on a TTM basis
Loading earnings history...
Lipella Pharmaceuticals Inc. (LIPO) Earnings Overview
As of June 24, 2026, Lipella Pharmaceuticals Inc. (LIPO) reported trailing twelve-month net income of -$5M, reflecting +22.2% year-over-year growth. The company earned $-1.17 per diluted share over the past four quarters, with a net profit margin of -935.2%.
Looking at the long-term picture, LIPO's historical earnings data spans multiple years. The company achieved its highest annual net income of -$61,656 in fiscal 2020.
Lipella Pharmaceuticals Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including SIGA ($20M net income, 24.6% margin), NUVL (-$450M net income), INVA ($504M net income, 63.8% margin), LIPO has room to improve margins relative to the peer group. Compare LIPO vs SIGA →
LIPO Earnings vs Peers
Earnings metrics vs comparable public companies
LIPO Historical Earnings Data (2019–2024)
6 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$5M | -8.6% | -$5M | $-4.79 | -935.2% | -947.2% |
| 2023 | -$5M | -77.8% | -$5M | $-6.16 | -1027.3% | -1055.6% |
| 2022 | -$3M | -39.3% | -$3M | $-5.12 | -1410.6% | -1406.3% |
| 2021 | -$2M | -2925.6% | -$2M | $-4.38 | -719.3% | -738.7% |
| 2020 | $-61,656 | +0.3% | $-56,862 | $-0.23 | -6.4% | -5.9% |
| 2019 | $-61,848 | - | $-53,791 | $-0.24 | -8.9% | -7.7% |
Download Data
Export LIPO earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
7+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
LIPO — Frequently Asked Questions
Quick answers to the most common questions about buying LIPO stock.
What is LIPO earnings per share (EPS)?
LIPO trailing twelve-month (TTM) diluted EPS is $-1.17, reflecting +22.2% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2019 to 2024 is available in the table on this page.
What is Lipella Pharmaceuticals Inc.'s net income?
Lipella Pharmaceuticals Inc. (LIPO) trailing twelve-month net income is $-5M as of 2024. Earnings grew +22.2% year-over-year.
Is LIPO profitable?
LIPO is not currently profitable on a TTM basis, reporting a net loss of $-5M. Net margin is -935.2%. Investors should monitor for a return to profitability.
What is LIPO's earnings growth rate?
LIPO compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2019 to 2024.
What are LIPO's profit margins?
Lipella Pharmaceuticals Inc. net profit margin is -935.2%, operating margin is -947.2%, and gross margin is -573.7%. Below-average margins reflect competitive or cost pressures. Return on Equity is -198.1%.
Is LIPO growing earnings?
Yes, LIPO earnings are accelerating — EPS growth of +22.2% exceeds the 5-year CAGR of N/A. TTM net income reached $-5M. Earnings momentum is strengthening.
What was LIPO's best earnings year?
Lipella Pharmaceuticals Inc.'s highest annual net income on record is $-61656.00, achieved in fiscal year 2020. Earnings history on this page spans 2019 to 2024 and includes all annual and quarterly figures.
What were LIPO's earnings last quarter?
LIPO's most recent reported quarter was Q3 2025. Net income was $-1M with diluted EPS of $-0.28. For a full breakdown of all quarters, see the quarterly earnings table on this page.